Key challenges for drugs in clinical development for cholangiocarcinoma-Reference-Cited by-同舟云学术

Key challenges for drugs in clinical development for cholangiocarcinoma

Published:2021-02-02 Issue:4 Volume:30 Page:285-290
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Keenan Bridget P.¹^ORCID,Kelley R. Kate (Katie)¹

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine, University of California San Francisco and Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2021.1880565

Reference34 articles.

1. Cholangiocarcinoma — evolving concepts and therapeutic strategies

2. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

3. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

4. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

5. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer;Current Treatment Options in Oncology;2024-07-27

2. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer;JAMA Oncology;2023-05-01

3. Epidermal growth factor rs4444903 polymorphism and risk of cholangiocarcinoma. A case control study;Clinical and Experimental Hepatology;2023

4. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma;The Oncologist;2022-08-04

5. Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach;Cancers;2022-01-13